Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Symptoms, Health-Related Quality of Life, and Tolerability of Loncastuximab Tesirine in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma

Alexander I. Spira, PhD MD FACP, Lei Chen, MD PhD, Xiaolei Zhou, Ari Gnanasakthy, Luqiang Wang, David Ungar, Rafael Curiel, John A. Radford, MD FMedSci, Brad S. Kahl, MD

Blood (2020) 136 (Supplement 1): 3–4.

https://doi.org/10.1182/blood-2020-139571

Published: 2020

Journal Articles

Characteristics and Treatment Patterns of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Who Received ≥3 Lines of Therapies

Jipan Xie, MD PhD, Aozhou Wu, PhD, Laura Liao, MS, Xiaoyan Du, MESc, Ahmed Noman, BA, Yawen Liang, PhD, Joseph Camardo, MD, Lei Chen, MD PhD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-140136

Published: 2020

Journal Articles

Treatment Patterns and Healthcare Costs in Newly Diagnosed Patients with Chronic Myeloid Leukemia Receiving Dasatinib or Nilotinib As First-Line Therapy in the United States: A Retrospective Claims Database Analysis

Lei Chen, MD PhD, Dominick Latremouille-Viau, MSc, Annie Guerin, MSc, Roy Nitulescu, MSc, Patrick Gagnon-Sanschagrin, BSc

Blood (2015) 126 (23): 1596.

https://doi.org/10.1182/blood.V126.23.1596.1596

Published: 2015

Journal Articles

Comparison of Survival Rates, Healthcare Resource Use and Costs of Elderly Patients with Chronic Myeloid Leukemia Receiving Dasatinib or Nilotinib As Second-Line Therapy

B. Douglas Smith, MD, Jun Liu, PhD, Dominick Latremouille-Viau, MSc, Zhou Zhou, MSc, Annie Guerin, MSc, Daniel Fernandez, MA, Dingdong Yi, BS, Xufei Wang, MA, Eric Q Wu, PhD, Shivani K Mhatre, MSc, Christopher H Keir, MD, Lei Chen, MD PhD

Blood (2014) 124 (21): 2618.

https://doi.org/10.1182/blood.V124.21.2618.2618

Published: 2014

Journal Articles

A Retrospective Analysis of Treatment Patterns in Elderly Patients with Chronic Myeloid Leukemia Receiving Dasatinib or Nilotinib As Second-Line Therapy after Imatinib

Blood (2014) 124 (21): 1293.

https://doi.org/10.1182/blood.V124.21.1293.1293

Published: 2014

Journal Articles

Twelve-Month Cost per Responder (CPR) Analysis of Nilotinib and Dasatinib As Front-Line Therapy in Patients with Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Annie Guerin, MSc, Cindy Revol, MPH, Agnihotram V. Ramanakumar, PhD, Rebekah Foster, BA, Eric Qiong Wu, PhD, Shivani K Mhatre, MSc, Lei Chen, MD PhD

Blood (2014) 124 (21): 1304.

https://doi.org/10.1182/blood.V124.21.1304.1304

Published: 2014

Journal Articles

Treatment and Management of Chronic Myelogenous Leukemia in Patients Cared for in a Large HMO

Reina Haque, PhD MPH, Jiaxiao Shi, PhD, Joanie Chung, MPH, Chantal C Avila, MA, Lei Chen, MD PhD, Joanne E Schottinger, MD

Blood (2014) 124 (21): 1310.

https://doi.org/10.1182/blood.V124.21.1310.1310

Published: 2014

Journal Articles

Impact Of Low-Grade Adverse Events (AEs) On Health-Related Quality Of Life (HRQoL) In Adult Patients With Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia In Chronic Phase (Ph+ CML-CP) From The Enestnd Trial: 48-Month Follow-Up

Lei Chen, MD, PhD, Annie Guerin, MSc, Maryna Marynchenko, MBA, Raluca Ionescu-Ittu, PhD, Robert Hiscock, MSc, Roy Nitulescu, MA, Chopra Pooja, MSc, Ling-I Hsu, MPH, Christopher Keir, MD, Eric Qiong Wu, PhD

Blood (2013) 122 (21): 4038.

https://doi.org/10.1182/blood.V122.21.4038.4038

Published: 2013

Journal Articles

Treatment Patterns Among Patients with Philadelphia Chromosome Positive Chronic Myeloid Leukemia (Ph+ CML) Treated with Imatinib in a Community Setting.

Kavita R Sail, MS, PhD, Lei Chen, MD, PhD, James Jackson, PharmD, MPH, Solveig G. Ericson, MD, PhD, Sally Haislip, RPh, Tamara Ibison, RN, James Gilmore, PharmD, Mansoor N Saleh, MD

Blood (2012) 120 (21): 3179.

https://doi.org/10.1182/blood.V120.21.3179.3179

Published: 2012

Journal Articles

Characteristics of Patients with Chronic Myelogenous Leukemia in Chronic Phase Switched to Nilotinib or Dasatinib As Second-Line Therapy

Alexander R. Macalalad, MD, Lei Chen, MD PhD, Annie Guerin, MSc, Jiayuan Luo, MSc, Eric Qiong Wu, PhD, James D. Griffin, MD

Blood (2012) 120 (21): 4447.

https://doi.org/10.1182/blood.V120.21.4447.4447

Published: 2012

Journal Articles

Comparison of Treatment Changes for Patients with Chronic Myelogenous Leukemia in Chronic Phase Switched From Imatinib to Nilotinib or Dasatinib As Second-Line Therapy

Alexander R. Macalalad, MD, Lei Chen, MD, PhD, Annie Guerin, MSc, Jiayuan Luo, MSc, Eric Qiong Wu, PhD, James D. Griffin, MD

Blood (2012) 120 (21): 4443.

https://doi.org/10.1182/blood.V120.21.4443.4443

Published: 2012

Journal Articles

Frequency of Molecular Monitoring Correlates with Long Term Outcomes in Chronic Phase Chronic Myelogenous Leukemia Treated with First-Line Imatinib: Results of a Community Survey

Stuart L. Goldberg, MD, Lei Chen, MD, PhD, Solveig G. Ericson, MD, PhD, Alexander R. Macalalad, MD, Annie Guerin, MSc, Nathan Liu, MPH, Michael Kaminsky, BSc, Eric Qiong Wu, PhD

Blood (2012) 120 (21): 1685.

https://doi.org/10.1182/blood.V120.21.1685.1685

Published: 2012

Journal Articles

Monitoring Patterns and Subsequent Outcomes Among Patients with Philadelphia Chromosome Positive Chronic Myeloid Leukemia (Ph+ CML) Treated with Imatinib in a Community Setting

James Jackson, PharmD, MPH, Lei Chen, MD, PhD, Kavita R Sail, MS, PhD, Solveig G. Ericson, MD, PhD, Sally Haislip, RPh, Joyce Sharpe, RN, James Gilmore, PharmD, Mansoor N Saleh, MD

Blood (2012) 120 (21): 2066.

https://doi.org/10.1182/blood.V120.21.2066.2066

Published: 2012

Journal Articles

Benefits of Early Switching From Imatinib to a Second-Generation Tyrosine Kinase Inhibitor Following 12 Month Complete Cytogenetic Response Failure: A Chart Review Analysis.

Daniel J. DeAngelo, MD, PhD, Lei Chen, MD, PhD, Annie Guerin, MSc, Amy Styles, MSc, Clemence Aberki, BSc, Philippe Giguere-Duval, BSc, Eric Qiong Wu, PhD

Blood (2012) 120 (21): 2792.

https://doi.org/10.1182/blood.V120.21.2792.2792

Published: 2012

Journal Articles

Comparison of Disease Outcomes for Patients with Chronic Myelogenous Leukemia in Chronic Phase Switched to Nilotinib or Dasatinib As Second-Line Therapy.

James D. Griffin, MD, Annie Guerin, MSc, Lei Chen, MD, PhD, Alexander R. Macalalad, MD, Jiayuan Luo, MSc, Eric Qiong Wu, PhD

Blood (2012) 120 (21): 2796.

https://doi.org/10.1182/blood.V120.21.2796.2796

Published: 2012

NARROW

Symptoms, Health-Related Quality of Life, and Tolerability of Loncastuximab Tesirine in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma

Characteristics and Treatment Patterns of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Who Received ≥3 Lines of Therapies

Treatment Patterns and Healthcare Costs in Newly Diagnosed Patients with Chronic Myeloid Leukemia Receiving Dasatinib or Nilotinib As First-Line Therapy in the United States: A Retrospective Claims Database Analysis

Comparison of Survival Rates, Healthcare Resource Use and Costs of Elderly Patients with Chronic Myeloid Leukemia Receiving Dasatinib or Nilotinib As Second-Line Therapy

A Retrospective Analysis of Treatment Patterns in Elderly Patients with Chronic Myeloid Leukemia Receiving Dasatinib or Nilotinib As Second-Line Therapy after Imatinib

Twelve-Month Cost per Responder (CPR) Analysis of Nilotinib and Dasatinib As Front-Line Therapy in Patients with Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Treatment and Management of Chronic Myelogenous Leukemia in Patients Cared for in a Large HMO

Impact Of Low-Grade Adverse Events (AEs) On Health-Related Quality Of Life (HRQoL) In Adult Patients With Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia In Chronic Phase (Ph+ CML-CP) From The Enestnd Trial: 48-Month Follow-Up

Treatment Patterns Among Patients with Philadelphia Chromosome Positive Chronic Myeloid Leukemia (Ph+ CML) Treated with Imatinib in a Community Setting.

Characteristics of Patients with Chronic Myelogenous Leukemia in Chronic Phase Switched to Nilotinib or Dasatinib As Second-Line Therapy

Comparison of Treatment Changes for Patients with Chronic Myelogenous Leukemia in Chronic Phase Switched From Imatinib to Nilotinib or Dasatinib As Second-Line Therapy

Frequency of Molecular Monitoring Correlates with Long Term Outcomes in Chronic Phase Chronic Myelogenous Leukemia Treated with First-Line Imatinib: Results of a Community Survey

Monitoring Patterns and Subsequent Outcomes Among Patients with Philadelphia Chromosome Positive Chronic Myeloid Leukemia (Ph+ CML) Treated with Imatinib in a Community Setting

Benefits of Early Switching From Imatinib to a Second-Generation Tyrosine Kinase Inhibitor Following 12 Month Complete Cytogenetic Response Failure: A Chart Review Analysis.

Comparison of Disease Outcomes for Patients with Chronic Myelogenous Leukemia in Chronic Phase Switched to Nilotinib or Dasatinib As Second-Line Therapy.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only